MedTrace Logo

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

NCT00386685 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2011-04-12

No results posted yet for this study

Summary

The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.

The secondary objectives are safety and pharmacokinetic interaction

Conditions

  • Breast Neoplasms

Interventions

DRUG

larotaxel (XRP9881)

intravenous administration

DRUG

trastuzumab

intravenous administration

Sponsors & Collaborators

Principal Investigators

  • Henri Roche, PhD · Institut Claudius Regaud - Toulouse - France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-10-31
Completion
2011-01-31

Countries

  • Belgium
  • France
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00386685 on ClinicalTrials.gov